1. Home
  2. SDST vs NCEL Comparison

SDST vs NCEL Comparison

Compare SDST & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stardust Power Inc.

SDST

Stardust Power Inc.

HOLD

Current Price

$0.14

Market Cap

16.5M

Sector

Finance

ML Signal

HOLD

Logo NewcelX Ltd. Ordinary Shares

NCEL

NewcelX Ltd. Ordinary Shares

HOLD

Current Price

$3.31

Market Cap

19.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SDST
NCEL
Founded
2022
2008
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.5M
19.4M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
SDST
NCEL
Price
$0.14
$3.31
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
752.5K
7.1K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.15
$1.83
52 Week High
$7.67
$5.12

Technical Indicators

Market Signals
Indicator
SDST
NCEL
Relative Strength Index (RSI) 17.49 48.24
Support Level N/A $3.01
Resistance Level $0.73 $3.60
Average True Range (ATR) 0.05 0.18
MACD 0.01 0.01
Stochastic Oscillator 3.34 41.46

Price Performance

Historical Comparison
SDST
NCEL

About SDST Stardust Power Inc.

Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.

Share on Social Networks: